Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Neoplasms of the CNS

  Free Subscription


Articles published in Acta Neuropathol

Retrieve available abstracts of 98 articles:
HTML format



Single Articles


    December 2023
  1. HICKMAN RA, Gedvilaite E, Ptashkin R, Reiner AS, et al
    CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas.
    Acta Neuropathol. 2023;146:845-847.
    PubMed    


  2. RAHMANZADE R, Pfaff E, Banan R, Sievers P, et al
    Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics.
    Acta Neuropathol. 2023;146:853-856.
    PubMed    


    October 2023
  3. MAAS SLN, Sievers P, Weber DC, Weller M, et al
    Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042-26042.
    Acta Neuropathol. 2023 Oct 19. doi: 10.1007/s00401-023-02642.
    PubMed    


  4. ROBERTS HJ, Ji S, Picca A, Sanson M, et al
    Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations.
    Acta Neuropathol. 2023 Oct 18. doi: 10.1007/s00401-023-02640.
    PubMed    


  5. PICARD D, Felsberg J, Langini M, Stachura P, et al
    Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytoma.
    Acta Neuropathol. 2023;146:551-564.
    PubMed     Abstract available


    September 2023
  6. BOETTO J, Plu I, Ducos Y, Blouin A, et al
    Normal meninges harbor oncogenic somatic mutations in meningioma-driver genes.
    Acta Neuropathol. 2023 Sep 26. doi: 10.1007/s00401-023-02635.
    PubMed    


  7. TRAN QT, Upadhyaya SA, Billups CA, Onar-Thomas A, et al
    DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts.
    Acta Neuropathol. 2023;146:543-545.
    PubMed    


  8. JOHANN PD, Altendorf L, Efremova EM, Holsten T, et al
    Recurrent atypical teratoid/rhabdoid tumors (AT/RT) reveal discrete features of progression on histology, epigenetics, copy number profiling, and transcriptomics.
    Acta Neuropathol. 2023;146:527-541.
    PubMed     Abstract available


    August 2023
  9. WIRSCHING HG, Felsberg J, Prummer M, Moisoiu V, et al
    Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival.
    Acta Neuropathol. 2023 Aug 13. doi: 10.1007/s00401-023-02617.
    PubMed    


    July 2023
  10. WILLIAMS EA, Brastianos PK, Wakimoto H, Zolal A, et al
    A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Acta Neuropathol. 2023 Jul 31. doi: 10.1007/s00401-023-02609.
    PubMed     Abstract available


    June 2023
  11. MEDICI G, Freudenmann LK, Velz J, Wang SS, et al
    A T-cell antigen atlas for meningioma: novel options for immunotherapy.
    Acta Neuropathol. 2023 Jun 27. doi: 10.1007/s00401-023-02605.
    PubMed     Abstract available


  12. MADLENER S, Furtner J, Stepien N, Senfter D, et al
    Clinical applicability of miR517a detection in liquid biopsies of ETMR patients.
    Acta Neuropathol. 2023;145:843-846.
    PubMed    


    May 2023
  13. WANG JZ, Patil V, Liu J, Dogan H, et al
    Correction: Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.
    Acta Neuropathol. 2023 May 12. doi: 10.1007/s00401-023-02584.
    PubMed    


    April 2023
  14. KORSHUNOV A, Okonechnikov K, Schrimpf D, Tonn S, et al
    Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
    Acta Neuropathol. 2023 Apr 24. doi: 10.1007/s00401-023-02575.
    PubMed     Abstract available


  15. WANG JZ, Patil V, Liu J, Dogan H, et al
    Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.
    Acta Neuropathol. 2023 Apr 24. doi: 10.1007/s00401-023-02571.
    PubMed     Abstract available


  16. GODDARD J, Castle J, Southworth E, Fletcher A, et al
    Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.
    Acta Neuropathol. 2023 Apr 4. doi: 10.1007/s00401-023-02566.
    PubMed     Abstract available


    March 2023
  17. BOGUMIL H, Sill M, Schrimpf D, Ismer B, et al
    Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions.
    Acta Neuropathol. 2023 Mar 18. doi: 10.1007/s00401-023-02558.
    PubMed     Abstract available


  18. JAMSHIDI P, McCord M, Galbraith K, Santana-Santos L, et al
    Variant allelic frequency of driver mutations predicts success of genomic DNA methylation classification in central nervous system tumors.
    Acta Neuropathol. 2023;145:365-367.
    PubMed    


    February 2023
  19. KHAN AB, English CW, Chen WC, Athukuri P, et al
    Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma.
    Acta Neuropathol. 2023 Feb 2. doi: 10.1007/s00401-023-02543.
    PubMed    


  20. TANG V, Lu R, Mirchia K, Van Ziffle J, et al
    Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas.
    Acta Neuropathol. 2023 Feb 1. doi: 10.1007/s00401-023-02544.
    PubMed    


    January 2023
  21. KECK MK, Sill M, Wittmann A, Joshi P, et al
    Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification.
    Acta Neuropathol. 2023;145:49-69.
    PubMed     Abstract available


  22. CIMINO PJ, Ketchum C, Turakulov R, Singh O, et al
    Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1.
    Acta Neuropathol. 2023;145:71-82.
    PubMed     Abstract available


  23. METAIS A, Bouchoucha Y, Kergrohen T, Dangouloff-Ros V, et al
    Pediatric spinal pilocytic astrocytomas form a distinct epigenetic subclass from pilocytic astrocytomas of other locations and diffuse leptomeningeal glioneuronal tumours.
    Acta Neuropathol. 2023;145:83-95.
    PubMed     Abstract available


    December 2022
  24. EBRAHIMI A, Herrlinger U, Waha A, Kaluza L, et al
    Methylation class oligosarcoma may encompass IDH-wildtype gliomas.
    Acta Neuropathol. 2022 Dec 15. doi: 10.1007/s00401-022-02529.
    PubMed    


  25. MYNAREK M, Obrecht D, Sill M, Sturm D, et al
    Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.
    Acta Neuropathol. 2022 Dec 2. doi: 10.1007/s00401-022-02522.
    PubMed     Abstract available


  26. CHIANG J, Moreira DC, Li X, Furtado LV, et al
    Prognostic significance of chromosome arm 1q gain and methylation class in molecularly defined diffuse leptomeningeal glioneuronal tumor.
    Acta Neuropathol. 2022;144:1185-1187.
    PubMed    


  27. TAUZIEDE-ESPARIAT A, Volodia-Dangouloff-Ros, Figarella-Branger D, Uro-Coste E, et al
    Clinicopathological and molecular characterization of three cases classified by DNA-methylation profiling as "Glioneuronal Tumors, NOS, Subtype A".
    Acta Neuropathol. 2022;144:1179-1183.
    PubMed    


    November 2022
  28. GOTTARDO NG
    Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas: "it's a numbers game"-implications for WNT medulloblastoma dose-reduction clinical trials.
    Acta Neuropathol. 2022 Nov 20. doi: 10.1007/s00401-022-02518.
    PubMed    


    October 2022
  29. WU Z, Rajan S, Chung HJ, Raffeld M, et al
    Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusions.
    Acta Neuropathol. 2022 Oct 6. pii: 10.1007/s00401-022-02508.
    PubMed    


  30. LIU APY, Dhanda SK, Lin T, Sioson E, et al
    Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials.
    Acta Neuropathol. 2022;144:733-746.
    PubMed     Abstract available


  31. MESSIAEN J, Claeys A, Shetty A, Spans L, et al
    Generation of patient-derived models from a metastatic pediatric diffuse leptomeningeal glioneuronal tumor with KIAA1549::BRAF fusion.
    Acta Neuropathol. 2022;144:793-797.
    PubMed    


  32. GOSCHZIK T, Mynarek M, Doerner E, Schenk A, et al
    Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas.
    Acta Neuropathol. 2022 Oct 1. pii: 10.1007/s00401-022-02505.
    PubMed     Abstract available


    September 2022
  33. TATARI N, Khan S, Livingstone J, Zhai K, et al
    The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers.
    Acta Neuropathol. 2022 Sep 30. pii: 10.1007/s00401-022-02506.
    PubMed     Abstract available


  34. RICKLEFS FL, Fita KD, Mohme M, Mawrin C, et al
    Genetic and epigenetic profiling identifies two distinct classes of spinal meningiomas.
    Acta Neuropathol. 2022 Sep 27. pii: 10.1007/s00401-022-02504.
    PubMed    


  35. SIDDAWAY R, Canty L, Pajovic S, Milos S, et al
    Oncohistone interactome profiling uncovers contrasting oncogenic mechanisms and identifies potential therapeutic targets in high grade glioma.
    Acta Neuropathol. 2022 Sep 7. pii: 10.1007/s00401-022-02489.
    PubMed     Abstract available


    August 2022
  36. DOGAN H, Blume C, Patel A, Jungwirth G, et al
    Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas.
    Acta Neuropathol. 2022 Aug 19. pii: 10.1007/s00401-022-02485.
    PubMed    


  37. LUCAS CG, Sloan EA, Gupta R, Wu J, et al
    Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.
    Acta Neuropathol. 2022 Aug 9. pii: 10.1007/s00401-022-02478.
    PubMed     Abstract available


  38. HUA L, Alkhatib M, Podlesek D, Gunther L, et al
    Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord.
    Acta Neuropathol. 2022 Aug 9. pii: 10.1007/s00401-022-02474.
    PubMed    


  39. PRATT D, Lucas CG, Selvam PP, Abdullaev Z, et al
    Recurrent ACVR1 mutations in posterior fossa ependymoma.
    Acta Neuropathol. 2022;144:373-376.
    PubMed    


    July 2022
  40. DANILENKO M, Zaka M, Keeling C, Crosier S, et al
    Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development.
    Acta Neuropathol. 2022 Jul 13. pii: 10.1007/s00401-022-02464.
    PubMed     Abstract available


    June 2022
  41. KORSHUNOV A, Okonechnikov K, Stichel D, Schrimpf D, et al
    Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression.
    Acta Neuropathol. 2022 Jun 30. pii: 10.1007/s00401-022-02460.
    PubMed     Abstract available


  42. VASUDEVAN HN, Choudhury A, Hilz S, Villanueva-Meyer JE, et al
    Intratumor and informatic heterogeneity influence meningioma molecular classification.
    Acta Neuropathol. 2022 Jun 27. pii: 10.1007/s00401-022-02455.
    PubMed    


  43. ADEBERG S, Knoll M, Koelsche C, Bernhardt D, et al
    DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma.
    Acta Neuropathol. 2022 Jun 4. pii: 10.1007/s00401-022-02443.
    PubMed     Abstract available


  44. FEDERICO A, Thomas C, Miskiewicz K, Woltering N, et al
    ATRT-SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance.
    Acta Neuropathol. 2022;143:697-711.
    PubMed     Abstract available


    May 2022
  45. WU Z, Lopes Abath Neto O, Bale TA, Benhamida J, et al
    DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival.
    Acta Neuropathol. 2022 May 14. pii: 10.1007/s00401-022-02430.
    PubMed    


  46. PATEL A, Dogan H, Payne A, Krause E, et al
    Rapid-CNS(2): rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study.
    Acta Neuropathol. 2022;143:609-612.
    PubMed    


    April 2022
  47. FLASCH DA, Chen X, Ju B, Li X, et al
    Somatic LINE-1 promoter acquisition drives oncogenic FOXR2 activation in pediatric brain tumor.
    Acta Neuropathol. 2022 Apr 11. pii: 10.1007/s00401-022-02420.
    PubMed    


  48. ROOSEN M, Ode Z, Bunt J, Kool M, et al
    The oncogenic fusion landscape in pediatric CNS neoplasms.
    Acta Neuropathol. 2022;143:427-451.
    PubMed     Abstract available


    March 2022
  49. LIU AP, Li KK, Chow C, Chan S, et al
    Expanding the clinical and molecular spectrum of pituitary blastoma.
    Acta Neuropathol. 2022;143:415-417.
    PubMed    


    February 2022
  50. TAUZIEDE-ESPARIAT A, Guerrini-Rousseau L, Perrier A, Torrejon J, et al
    Immunohistochemistry as a tool to identify ELP1-associated medulloblastoma.
    Acta Neuropathol. 2022 Feb 23. pii: 10.1007/s00401-022-02409.
    PubMed    


  51. PRATT D, Abdullaev Z, Papanicolau-Sengos A, Ketchum C, et al
    High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13.
    Acta Neuropathol. 2022 Feb 1. pii: 10.1007/s00401-022-02404.
    PubMed     Abstract available


  52. SUWALA AK, Felix M, Friedel D, Stichel D, et al
    Oligosarcomas, IDH-mutant are distinct and aggressive.
    Acta Neuropathol. 2022;143:263-281.
    PubMed     Abstract available


    January 2022
  53. MARKWELL SM, Ross JL, Olson CL, Brat DJ, et al
    Necrotic reshaping of the glioma microenvironment drives disease progression.
    Acta Neuropathol. 2022 Jan 17. pii: 10.1007/s00401-021-02401.
    PubMed     Abstract available


  54. LUCAS CG, Gupta R, Wu J, Shah K, et al
    EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma.
    Acta Neuropathol. 2022;143:109-113.
    PubMed    


  55. JENSEIT A, Camgoz A, Pfister SM, Kool M, et al
    EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
    Acta Neuropathol. 2022;143:1-13.
    PubMed     Abstract available


    December 2021
  56. LUCAS CG, Abdullaev Z, Bruggers CS, Mirchia K, et al
    Activating NTRK2 and ALK receptor tyrosine kinase fusions extend the molecular spectrum of pleomorphic xanthoastrocytomas of early childhood: a diagnostic overlap with infant-type hemispheric glioma.
    Acta Neuropathol. 2021 Dec 15. pii: 10.1007/s00401-021-02396.
    PubMed    


  57. CHONG AS, Han H, Albrecht S, Weon YC, et al
    DICER1 syndrome in a young adult with pituitary blastoma.
    Acta Neuropathol. 2021;142:1071-1076.
    PubMed    


  58. SCHMID S, Solomon DA, Perez E, Thieme A, et al
    Genetic and epigenetic characterization of posterior pituitary tumors.
    Acta Neuropathol. 2021;142:1025-1043.
    PubMed     Abstract available


    November 2021
  59. ALHALABI KT, Stichel D, Sievers P, Peterziel H, et al
    PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum.
    Acta Neuropathol. 2021;142:841-857.
    PubMed     Abstract available


  60. SIEVERS P, Henneken SC, Blume C, Sill M, et al
    Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors.
    Acta Neuropathol. 2021;142:827-839.
    PubMed     Abstract available


    September 2021
  61. SIEVERS P, Stichel D, Sill M, Schrimpf D, et al
    GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
    Acta Neuropathol. 2021 Sep 18. pii: 10.1007/s00401-021-02369.
    PubMed    


  62. KIRCHES E, Sahm F, Korshunov A, Bluecher C, et al
    Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas.
    Acta Neuropathol. 2021 Sep 8. pii: 10.1007/s00401-021-02351.
    PubMed     Abstract available


  63. GUPTA R, Lucas CG, Wu J, Barreto J, et al
    Low-grade glioneuronal tumors with FGFR2 fusion resolve into a single epigenetic group corresponding to 'Polymorphous low-grade neuroepithelial tumor of the young'.
    Acta Neuropathol. 2021;142:595-599.
    PubMed    


    August 2021
  64. COLTIN H, Sundaresan L, Smith KS, Skowron P, et al
    Subgroup and subtype-specific outcomes in adult medulloblastoma.
    Acta Neuropathol. 2021 Aug 18. pii: 10.1007/s00401-021-02358.
    PubMed     Abstract available


  65. LOTSCH D, Kirchhofer D, Englinger B, Jiang L, et al
    Targeting fibroblast growth factor receptors to combat aggressive ependymoma.
    Acta Neuropathol. 2021;142:339-360.
    PubMed     Abstract available


  66. PATHAK R, Zin F, Thomas C, Bens S, et al
    Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors.
    Acta Neuropathol. 2021;142:361-374.
    PubMed     Abstract available


    July 2021
  67. NAZIO F, Po A, Abballe L, Ballabio C, et al
    Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling.
    Acta Neuropathol. 2021 Jul 24. pii: 10.1007/s00401-021-02347.
    PubMed     Abstract available


  68. SCHOOF M, Kordes U, Volk AE, Al-Kershi S, et al
    Malignant gliomas with H3F3A G34R mutation or MYCN amplification in pediatric patients with Li Fraumeni syndrome.
    Acta Neuropathol. 2021 Jul 15. pii: 10.1007/s00401-021-02346.
    PubMed    


    June 2021
  69. FUJIMOTO K, Arita H, Satomi K, Yamasaki K, et al
    TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Acta Neuropathol. 2021 Jun 20. pii: 10.1007/s00401-021-02337.
    PubMed     Abstract available


  70. KRESBACH C, Dorostkar MM, Suwala AK, Wefers AK, et al
    Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype.
    Acta Neuropathol. 2021;141:971-974.
    PubMed    


  71. THOMAS C, Thierfelder F, Trager M, Soschinski P, et al
    TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
    Acta Neuropathol. 2021;141:959-970.
    PubMed     Abstract available


  72. TESILEANU CMS, Vallentgoed WR, Sanson M, Taal W, et al
    Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
    Acta Neuropathol. 2021;141:945-957.
    PubMed     Abstract available


  73. NADAF J, de Kock L, Chong AS, Korbonits M, et al
    Molecular characterization of DICER1-mutated pituitary blastoma.
    Acta Neuropathol. 2021;141:929-944.
    PubMed     Abstract available


    May 2021
  74. JAUNMUKTANE Z, Banerjee G, Paine S, Parry-Jones A, et al
    Alzheimer's disease neuropathological change three decades after iatrogenic amyloid-beta transmission.
    Acta Neuropathol. 2021 May 28. pii: 10.1007/s00401-021-02326.
    PubMed    


  75. LIU APY, Li BK, Pfaff E, Gudenas B, et al
    Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study.
    Acta Neuropathol. 2021;141:771-785.
    PubMed     Abstract available


    April 2021
  76. FORSTER A, Brand F, Banan R, Huneburg R, et al
    Rare germline variants in the E-cadherin gene CDH1 are associated with the risk of brain tumors of neuroepithelial and epithelial origin.
    Acta Neuropathol. 2021 Apr 30. pii: 10.1007/s00401-021-02307.
    PubMed     Abstract available


  77. SUWALA AK, Stichel D, Schrimpf D, Maas SLN, et al
    Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.
    Acta Neuropathol. 2021 Apr 19. pii: 10.1007/s00401-021-02302.
    PubMed     Abstract available


  78. RICKERT D, Bartl J, Picard D, Bernardi F, et al
    Circular RNA profiling distinguishes medullobastoma groups and shows aberrant RMST overexpression in WNT medulloblastoma.
    Acta Neuropathol. 2021 Apr 17. pii: 10.1007/s00401-021-02306.
    PubMed    


  79. PRATT D, Kumar-Sinha C, Cieslik M, Mehra R, et al
    A novel ATXN1-DUX4 fusion expands the spectrum of 'CIC-rearranged sarcoma' of the CNS to include non-CIC alterations.
    Acta Neuropathol. 2021;141:619-622.
    PubMed    


    March 2021
  80. ZSCHERNACK V, Junger ST, Mynarek M, Rutkowski S, et al
    Supratentorial ependymoma in childhood: more than just RELA or YAP.
    Acta Neuropathol. 2021;141:455-466.
    PubMed     Abstract available


    February 2021
  81. FISHER MJ, Jones DTW, Li Y, Guo X, et al
    Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1).
    Acta Neuropathol. 2021 Feb 14. pii: 10.1007/s00401-021-02276.
    PubMed     Abstract available


  82. SCHULLER U, Iglauer P, Dorostkar MM, Mawrin C, et al
    Correction to: Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations.
    Acta Neuropathol. 2021 Feb 9. pii: 10.1007/s00401-021-02273.
    PubMed    


  83. HOLDHOF D, Johann PD, Spohn M, Bockmayr M, et al
    Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.
    Acta Neuropathol. 2021;141:291-301.
    PubMed     Abstract available


    January 2021
  84. SCHULLER U, Iglauer P, Dorostkar MM, Mawrin C, et al
    Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations.
    Acta Neuropathol. 2021 Jan 12. pii: 10.1007/s00401-020-02259.
    PubMed    


  85. FUKUMURA K, Malgulwar PB, Fischer GM, Hu X, et al
    Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis.
    Acta Neuropathol. 2021 Jan 4. pii: 10.1007/s00401-020-02256.
    PubMed     Abstract available


  86. BALE TA, Sait SF, Benhamida J, Ptashkin R, et al
    Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY).
    Acta Neuropathol. 2021;141:123-125.
    PubMed    


  87. SUWALA AK, Stichel D, Schrimpf D, Kloor M, et al
    Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
    Acta Neuropathol. 2021;141:85-100.
    PubMed     Abstract available


    December 2020
  88. SIEVERS P, Sill M, Blume C, Tauziede-Espariat A, et al
    Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1.
    Acta Neuropathol. 2020 Dec 14. pii: 10.1007/s00401-020-02247.
    PubMed     Abstract available


    October 2020
  89. KEENAN C, Graham RT, Harreld JH, Lucas JT Jr, et al
    Infratentorial C11orf95-fused gliomas share histologic, immunophenotypic, and molecular characteristics of supratentorial RELA-fused ependymoma.
    Acta Neuropathol. 2020 Oct 24. pii: 10.1007/s00401-020-02238.
    PubMed    


  90. PASSOS J, Quidet M, Brahimi A, Flament C, et al
    Familial adenomatous polyposis associated craniopharyngioma secondary to both germline and somatic mutations in the APC gene.
    Acta Neuropathol. 2020 Oct 6. pii: 10.1007/s00401-020-02232.
    PubMed    


  91. GOLEBIEWSKA A, Hau AC, Oudin A, Stieber D, et al
    Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
    Acta Neuropathol. 2020 Oct 3. pii: 10.1007/s00401-020-02226.
    PubMed     Abstract available


    February 2020
  92. LIU APY, Gudenas B, Lin T, Orr BA, et al
    Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials.
    Acta Neuropathol. 2020;139:259-271.
    PubMed     Abstract available


  93. PFAFF E, Aichmuller C, Sill M, Stichel D, et al
    Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations.
    Acta Neuropathol. 2020;139:243-257.
    PubMed     Abstract available


  94. THOMAS C, Wefers A, Bens S, Nemes K, et al
    Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults.
    Acta Neuropathol. 2020;139:277-286.
    PubMed     Abstract available


  95. SIEVERS P, Schrimpf D, Stichel D, Reuss DE, et al
    Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation.
    Acta Neuropathol. 2020;139:403-406.
    PubMed    


  96. NEUMANN JE, Spohn M, Obrecht D, Mynarek M, et al
    Molecular characterization of histopathological ependymoma variants.
    Acta Neuropathol. 2020;139:305-318.
    PubMed     Abstract available


  97. GARETON A, Tauziede-Espariat A, Dangouloff-Ros V, Roux A, et al
    The histomolecular criteria established for adult anaplastic pilocytic astrocytoma are not applicable to the pediatric population.
    Acta Neuropathol. 2020;139:287-303.
    PubMed     Abstract available


    January 2020
  98. FELLER C, Felix M, Weiss T, Herold-Mende C, et al
    Histone epiproteomic profiling distinguishes oligodendroglioma, IDH-mutant and 1p/19q co-deleted from IDH-mutant astrocytoma and reveals less tri-methylation of H3K27 in oligodendrogliomas.
    Acta Neuropathol. 2020;139:211-213.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.